Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1291583 (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) in Healthy Male Subjects
Latest Information Update: 05 Mar 2020
At a glance
- Drugs BI 1291583 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 28 Feb 2020 Status changed from suspended to discontinued.
- 26 Nov 2019 Planned number of patients changed from 56 to 48.
- 26 Nov 2019 Planned End Date changed from 24 Mar 2020 to 13 Jul 2020.